Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.37 |
| ▸ | DPP4 | P27487 | 4/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | PAK4 | O96013 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30425209 | 1.00 | HDAC6 (0.37) | HDAC6DPP4ROCK2PAK4PIM1 | |
| SCHEMBL25387316 | 0.92 | DPP4 (0.35) | HDAC6DPP4FGFR1HDAC1FLT3 | |
| SCHEMBL30425648 | 0.92 | DPP4 (0.35) | HDAC6DPP4FGFR1HDAC1FLT3 | |
| SCHEMBL30424271 | 0.91 | HDAC1 (0.39) | HDAC6DPP4ROCK2PAK4PIM1 | |
| SCHEMBL25254154 | 0.91 | HDAC1 (0.39) | HDAC6DPP4ROCK2PAK4PIM1 | |
| SCHEMBL25387070 | 0.89 | HDAC6 (0.37) | HDAC6ROCK2PAK4PIM1GSK3B | |
| SCHEMBL30424911 | 0.89 | HDAC6 (0.37) | HDAC6ROCK2PAK4PIM1GSK3B | |
| SCHEMBL25217535 | 0.89 | HDAC6 (0.42) | HDAC6DPP4ROCK2PIM1GSK3B | |
| SCHEMBL30425015 | 0.89 | HDAC6 (0.42) | HDAC6DPP4ROCK2PIM1GSK3B | |
| SCHEMBL25214570 | 0.86 | HDAC6 (0.49) | HDAC6ROCK2PIM1GSK3BAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | ITALFARMACO SPA (IT) | 2023-09-14 | — | — | US | claimed |
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | ITALFARMACO SPA (IT) | 2023-09-14 | — | — | US | disclosed |
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | ITALFARMACO SPA (IT) | 2023-09-14 | — | — | US | disclosed |
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | ITALFARMACO SPA (IT) | 2023-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | HDAC6, HDAC1, HDAC3 | HDAC6 1/4885DPP4 1675/4885ROCK2 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.